Meme kanserinde proteazom inhibisyonunun ölüm reseptörleri üzerindeki etkisinin araştırılması

Breast cancer is one of the most common cancers in the world. Various modern methods of genetic modulation and modification have been developed for the treatment of breast cancer. Despite development of new strategies for the treatment of the malignancy, there are many new areas that need to be investigated. In this thesis study, we used the 26S proteasome inhibitor, bortezomib, to determine changes in the expression profiles of several death receptors in two breast cancer cell lines. Initially, the cells were treated with different concentrations of bortezomib to determine particular doses that are effective on the cell viability of two used breast cancer cell lines. MTT results revealed that increased bortezomib concentrations decrease cell viability in a dose dependent manner. In addition, we also tested bortezomib mediated potential changes in the expression of several death receptors that play important roles in the induction of apoptosis. We found that low concentration of bortezomib which is not toxic to breast cancer cells treatment modulates expression of FAS (CD95), DR4 (TRAIL-R1) and DR5(TRAIL-R2). These data suggest that low concentration of bortezomib modulates the expression of death receptors which may contribute to immunogenic cell death.